Eloxx Pharmaceuticals Inc (ELOX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$12.74-1.39%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ELOX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -67.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of —
ELOX — President transition
Dated 2026-10-21
Director — Geno J. Germano: The filing discloses the appointment of a new independent director to fill a newly created board seat, which is a routine governance action rather than an executive departure.
Why it matters: The company has used warrants and equity changes to raise capital. Another raise may add cash but can dilute current shares.
Worry ifAn 8-K or company release reports a new share or warrant sale to raise cash.
Less concerning ifThe next earnings update reports no new share or warrant sale and gives cash runway details.
Why it matters: The company has no revenue and is funding clinical work with capital raises. A clear clinical update can show what that cash supports.
Watch forThe Nov. 10 report names a clinical program, its next milestone, and a target date.
Also watch forThe Nov. 10 report gives no clinical milestone, or says a planned milestone is delayed.
Why it matters: Q2 operating and net losses were $4.45 million and $4.5 million. Larger losses may raise pressure to find more cash.
Worry ifQ3 operating loss exceeds $4.45 million, or net loss exceeds $4.5 million.
Less concerning ifQ3 operating loss is below $4.45 million and net loss is below $4.5 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$331 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $1,090 loss on $10,000 · 10.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,179 loss on $10,000 · 41.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.